Marimastat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized, double-blind, phase I/II trial

Clinical Cancer Research

Volumn 11, Issue 12, 2005, Pages 4437-4443

  Rosenbaum, Eli ^a   Zahurak, Marianna ^a   Sinibaldi, Victoria ^a   Carducci, Michael A ^a   Pili, Roberto ^a   Laufer, Menachem ^a   DeWeese, Theodore L ^a   Eisenberger, Mario A ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; CP 471358; GELATINASE A; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PLACEBO; PRINOMASTAT; PROSTATE SPECIFIC ANTIGEN; REBIMASTAT; TANOMASTAT; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; ERYTHEMA; HUMAN; MALE; MUSCULOSKELETAL DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYARTHRITIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; ANALYSIS OF VARIANCE; ARTHRALGIA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME; TREATMENT OUTCOME;

EID: 20444484501     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2252     Document Type: Article

References (38)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.
3. Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003;57:944-52.
4. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20:3376-85.
5. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003;57:915-28.
6. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
7. Eisenberger MA, Partin AW, Pound C, Roostelaar CV, Epstein J, Walsh P. Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy. Update [abstract]. Proc Am Soc Clin Oncol 2003;22:380.
8. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567-73.
9. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in thestate of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004;22:537-56.
10. Ray JM, Stetler-Stevenson WG. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995;14:908-17.
11. Chambers AF, Matrisian L. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
12. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45.
13. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis, [abstract]. Cancer Chemother Pharmacol 1999;43:S42-51.
14. Gonzalez-Avila G, Iturria C, Vadillo F, Teran L, Selman M, Perez-Tamayo R. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology 1998;66:5-16.
15. Davidson B, Goldberg I, Liokumovich P, et al. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 1998;17:295-301.
16. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998;160:1914-8.
17. Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999; 878:212-27.
18. Murray GI, Duncan ME, O'neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-2.
19. Murray GI, Duncan ME, O'neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-61.
20. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-9.
21. Benassi MS, Gamberi G, Magagnoli G, et al. Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol 2001;12:75-80.
22. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75.
23. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-93.
24. Eisenberger M, Sinibaldi V, Laufer M, et al. Phase I/+ pharmacokinetic evaluation of marimastat in patients with advanced prostate cancer [abstract]. Proc Am Soc Clin Oncol 2000;19:336.
25. Bramhall SR, Hallissey MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002;86:1864-70.
26. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7.
27. Sparano JA, Bernardo P, Gradishar WJ, et al. Randomized phase ill trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: an Eastern Cooperative Oncology Group trial (E2196) [abstract]. Proc Am Soc Clin Oncol 2002;21:173.
28. Planting AS, Van der Gaast A, Schöffski P, et al. A phase I and pharmacokinetic (PK) study of the matrix metalloproteinase inhibitor (MMPI), CP-471,358 in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2002;21:446.
29. Bissett D, Von Pawel J, Mercier R, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2002; 21:1183.
30. Rigas JR, Denham CA, Rinaldi DA, et al. Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22:2525.
31. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999;43:S61-8.
32. Rizvi NA, Humphrey JS, Ness EA, et al. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004;10:1963-70.
33. Miller KD, Saphner TJ, Waterhouse DM, et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 2004;10:1971-5.
34. Kelloff GJ, Coffey DS, Chabner BA, et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 2004;10:3927-33.
35. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002;20:153-9.
36. Primrose JN, Bleiberg H, Daniel F, et al. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 1999;79:509-14.
37. Rosemurgy A, Harris J, Langleben A, Casper E, Goode S, Rasmussen H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 1999;22:247-52.
38. Miller KD, Gradishar W, Schuchter L, et al. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol 2002;13:1220-4.